GC Pharma

Keyword Search
Plasma Derivatives Office Vaccines Subsidiary Pipeline R&D Media Stock Company Recruit
Product Search
Total Menu KOR


Green Cross Receives WHO Prequalification for GCFlu Quadrivalent

22 Dec, 2016

Yongin, South Korea, 22 December 2016 - Green Cross Corporation (Green Cross) (KRX: 006280), a South Korean biopharmaceutical company, announced today that World Health Organization (WHO) has prequalified its quadrivalent seasonal influenza vaccine, GCFlu Quadrivalent. WHO prequalification means that GCFlu Quadrivalent is now eligible for procurement by the United Nations agencies including the United Nations Children's Fund (UNICEF) and the Pan American Health Organization (PAHO), for use in national immunization programs.

This qualification status is based on a review of a comprehensive set of data related to the process and the product characteristics, as well as on a positive recommendation of WHO’s auditors following a site inspection of Green Cross Corporation's manufacturing facilities. 

“We are pleased to receive WHO prequalification as recognition that GCFlu Quadrivalent meets the organization’s high standards for quality,” said EC Huh, Ph. D., President of Green Cross Corporation. “It is a significant step in providing broader global access to this important vaccine for those who need it.”

GCFlu Quadrivalent was first approved in South Korea in November 2015. It is the newest addition to the GCFlu franchise which is administered to more than 100 million people in the world last 6 years.

About Green Cross Corporation
Green Cross Corporation (Green Cross) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, Green Cross is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for nearly half a century. 

This release includes forward-looking statements, which express the current beliefs and expectations of management. Such statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

# # #